MedTrace Logo

A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients

NCT01440920 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2021-03-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety, tolerability of OCV-501 in patients with acute myeloid leukemia (AML) who achieved complete remission after induction regimen and who completed a standard consolidation therapy.

Conditions

Interventions

DRUG

OCV-501

subcutaneously administered once a week, 4 times at the dose of 0.3 mg

DRUG

OCV-501

subcutaneously administered once a week, 4 times at the dose of 1 mg

DRUG

OCV-501

subcutaneously administered once a week, 4 times at the dose of 3 mg

Sponsors & Collaborators

  • Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2013-03-31
Completion
2013-07-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01440920 on ClinicalTrials.gov